MedTrace Logo

Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation

NCT00867685 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2009-04-30

No results posted yet for this study

Summary

The purpose of this study is to compare the liquid suspension form of AZD 2624 to a tablet form of the same drug. This study will also study the effect of food on the tablet form of the drug.

Conditions

  • Healthy

Interventions

DRUG

AZD2624

Single dose of 40 mg AZD2624 liquid suspension, PO

DRUG

AZD2624

Single dose of 40 mg AZD 2624 (2x20mg tablets), PO

Sponsors & Collaborators

Principal Investigators

  • Sylvan Hurewitz, MD · AstraZeneca Clinical Pharmacology Unit, US

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00867685 on ClinicalTrials.gov